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Clinical, epidemiological and molecular features
of the HIV-1 subtype C and recombinant forms
that are circulating in the city of São Paulo, Brazil
Rosana Alcalde1*†, Monick L Guimarães3†, Alberto JS Duarte1 and Jorge Casseb1,2*
Abstract
Background: The city of Sao Paulo has the highest AIDS case rate, with nearly 60% in Brazil. Despite, several
studies involving molecular epidemiology, lack of data regarding a large cohort study has not been published from
this city.
Objectives: This study aimed to describe the HIV-1 subtypes, recombinant forms and drug resistance mutations,
according to subtype, with emphasis on subtype C and BC recombinants in the city of São Paulo, Brazil.
Study design: RNA was extracted from the plasma samples of 302 HIV-1-seropositive subjects, of which 211 were
drug-naive and 82 were exposed to ART. HIV-1 partial pol region sequences were used in phylogenetic analyses for
subtyping and identification of drug resistance mutations. The envelope gene of subtype C and BC samples was
also sequenced.
Results: From partial pol gene analyses, 239 samples (79.1%) were assigned as subtype B, 23 (7.6%) were F1,
16 (5.3%) were subtype C and 24 (8%) were mosaics (3 CRF28/CRF29-like). The subtype C and BC recombinants
were mainly identified in drug-naïve patients (72.7%) and the heterosexual risk exposure category (86.3%), whereas
for subtype B, these values were 69.9% and 57.3%, respectively (p = 0.97 and p= 0.015, respectively). An increasing
trend of subtype C and BC recombinants was observed (p < 0.01).
Conclusion: The HIV-1 subtype C and CRFs seem to have emerged over the last few years in the city of São Paulo,
principally among the heterosexual population. These findings may have an impact on preventive measures and
vaccine development in Brazil.
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Background
The huge genetic variability of HIV-1 results in a com-
plex and dynamic molecular classification of types (HIV-
1 and 2), groups (M,N,O,P), and the pandemic group M
could be divided into subtypes (A-D,F-H,J,K) and recom-
binant forms, such as circulating recombinant forms
(CRF) and unique recombinant forms (URF). Such HIV-
1 variation has an important impact on diagnosis, viral
load measurement and the performance of HIV-1
genotyping systems [1-3]. Thus, HIV-1 subtypes also
contribute to the capacity of HIV-1 to evade the host
immune response, [4] which can affect the response to
antiretroviral treatment and, consequently, to the emer-
gence of drug resistance [5]. Some studies have sug-
gested that coreceptor switching from CCR5 to CXCR4
is less common in HIV-1 subtype C, [6] showing a lower
rate of accumulation of mutations that confer resistance
than subtype B [5]. Concerning the replication fitness of
subtype C, the studies were controversial, [7-9] and in
relation to transmission in utero, this subtype presented
high efficiency compared to subtypes A or D [8,10,11].
These properties suggest an overall transmission advan-
tage, in part, possibly related to efficient replication in
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dendritic cells, the targets of the onset of HIV-1 infec-
tion [11].
Although HIV-1 subtype B is the most studied, HIV-1
C predominates globally and is responsible for approxi-
mately 50% of infections [12]. This subtype is not wide-
spread, but it is the most prevalent in sub-Saharan
Africa and in the populous countries, such as India and
China, where HIV infection rates are highest among het-
erosexuals [12,13]. Up to now, five circulating recombin-
ant forms (CRFs) involving this subtype have been
detected, three of them presenting recombinations be-
tween subtypes B and C, CRF07, CRF08, described in
China, [14,15] and CRF31_BC, described in Brazil [16].
The other two present recombinations between subtypes
C and D, CRF10_CD and CRF41_CD [17,18]. Overall,
more than 18% of new infections have been attributed to
HIV-1 recombinants [19].
The Brazilian AIDS epidemic is mainly driven by
subtypes B, F1, and BF1 recombinants; however, in the
Southern region, subtype C and BC recombinants can
represent up to 50% of cases, depending of the geo-
graphical studied region [20-27]. Despite the documen-
ted early circulation of HIV-1 subtype C outside of the
southern region in 1992, one case from the city of São
Paulo [28] and another in 1986 in Santos, [29] only
recently has a continuous increase in cases been
observed [30-32].
The current study was conducted to determine HIV-1
genetic diversity and PI/RTI resistance associated muta-
tions among HIV-1 infected drug naïve and HAART
patients in a cohort in the city of São Paulo. Moreover,
patients classified as HIV-1 subtype C and BC recombi-
nants were analyzed in more details.
Objectives
The present study aimed to describe HIV-1 subtypes,
CRFs and drug resistance mutations in drug-naïve and
failing HAART individuals living in the city of São
Paulo, in particular attention to those classified as sub-
type C and BC.
Study design
Study population
The study population was composed by HIV-1-infected
patients who have been followed-up at the Ambulatory
Service of the Department of Secondary Immunodeficiency
Clinic of the Clinical Hospital, University of São Paulo
Medical School (HC/FMUSP), São Paulo, SP, Brazil, one of
the largest teaching and research hospitals in Brazil.
According to the Brazilian Ministry of Health, HIV
genotyping test should be routinely performed in
patients under antiretroviral therapy who present a
plasma viral load over 2000 copies/mL [33]. Following
this directive, a total of 82 patients were genotyped at
HC/FMUSP from March 2002 to June 2010. During the
same period, 211 drug-naive individuals and nine indivi-
duals who had unknown status in relation to antiretro-
viral therapy (ART) were also genotyped. Demographic
and clinical data were obtained from clinical charts or
direct interview and the patients individually allow us
for publication, as shown at Table 1. This study protocol
was approved by the Research Ethics Committee of HC/
FMUSP, under protocol number 774/99, and written
informed consent was obtained from all patients. During
the follow-up, CD4+T cells and HIV-1 viral load were
determined using the Brazilian Ministry of Health
guidelines.
RNA isolation, RT-PCR and DNA sequencing
HIV-1 viral RNA was isolated from plasma samples
using the QIAampW Viral RNA Mini Kit (Qiagen, Hilden,
Germany) extraction method, in accordance with the
manufacturer’s protocol. Complementary DNA was per-
formed by RT-PCR protocol with random primers and
using the PR/RT PCR strategy previously described by
Gonzales et al. [34,35]. The PCR products were puri-
fied using QIAquickW (Qiagen, Hilden, Germany), in
accordance with the manufacturer’s protocol. The PCR
purified products were sequenced utilizing ABI Prism Big
Dye Terminator Ready Reaction Kit version 3.0 (Applied
BiosystemsW, Foster City, CA), in accordance with their re-
spective protocols. The reactions were analyzed using the
ABI Prism 3100 Genetic Analyzer (Applied BiosystemsW,
Foster City, CA).
Sequence analysis
The chromatograms of all sequenced DNA were visu-
ally using the Sequencher program version 4.0.5 (Gene
Codes) and manually edited. PR/RT sequencing was
conducted to detect drug resistance mutations and
HIV-1 subtypes. Major antiretroviral drug resistance
mutations were classified according to Stanford Uni-
versity online HIV Drug Resistance Database, [36].
The International AIDS Society-USA Panel and Up-
date of the Drug Resistance Mutations in HIV-1,
Spring 2008 [37-39].
Nucleotide sequences were aligned using the Clustal X
program [40] and later hand edited for minor adjust-
ments and gap-stripped. An alignment of 860 bp that
partially covered the PR/RT region (nucleotides 2343-
3203) was used for phylogenetic inferences under
Neighbor-Joining (NJ) algorithm in Mega 4.0.2 program
[41]. In order to confirm the classification of the non-B
sequences, Bayesian analysis was performed. The jMo-
deltest 0.1.1 program [42] was used to select the best-fit
model of nucleotide substitution under the Akaike infor-
mation criteria, resulting in the choice of the GTR + I +
G model, [43] as implemented in MrBayes v3.1.2 [44].
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Table 1 Epidemiological, virological, immunological characteristics and resistance associated mutations of PR/RT region from patients classified as HIV-1
I.D. LIM56 Date
collection
Age
(years)
Gender VL CD4 Transmission
mode
Mutations
Protease
minor
Mutations other
(Protease)
Mutations
(NRTI)
Mutations
(NNRTI)
Mutations other (RT)
A- subtype C
01 22/09/2003 48 M 248000 163 heterosexual M36I, V82I,
I93L
E35D, N37K, R41N,
H69K, L89M
None None V35T, E36AE, T39E, S48T, K122E, I135T, K166R,
F171Y, K173A, Q174K, D177E, I202V, Q207E,
R211K, F214L, V245Q
02 25/09/2003 63 M 20500 254 heterosexual L10I, M36T,
I93L
T12P, K14R, I15V, L19I,
N37K, R41N, H69K, L89M
None None V35T, E36A, T39D, S48T, V60I, K122E, K173A,
D177E, T200V, Q207E, R211K
03 18/04/2005 31 M 62900 677 bisexual M36I, L63P,
I93L
T12A, N37K, R41N,
H69K, L89M
None None V35T, E36A, T39E, K43R, S48T, K122E,
D123S, I135T, K173A, D177E, Q207E,
R211K, F214L
04 23/05/2005 22 M 17400 528 heterosexual M36I, I93L R41K, H69K, L89M None None V35T, E36A, T39E, S48T, V60I, K64R,
K122E, D123N, I135T, A158S,
K173A, D177Q, Q207E, R211K
05 11/08/2005 37 F >500000 54 heterosexual M36I, L63P,
I93L
T12A, I15V, L19I, E21EQ,
N37K, R41N, H69K
None None V35T, T39E, S48T, I135T, K173A, Q174K,
D177E, T200A, Q207E, R211K, F214L
06 13/09/2005 37 M 24300 332 heterosexual M36I, L63P,
I93L
N37K, R41N, H69K,
L89M
None None V35T, E36AE, T39D, K43R, S48T, K122E,
D123N, K173A, D177E,V179I, G196E,
T200A, E204K, Q207E, R211K
07 10/04/2006 39 F 30500 252 heterosexual L10V, L63P,
I93L
T12AT, I15V, N37K,
R41N, H69K
None None V35T, E36A, T39D, S48T, K173A, T200A,
E204D, Q207AE, R211K
08 11/05/2006 44 M 122000 106 heterosexual M36I, I93L I15V, R41K, H69K,
T74A, L89M
None None K32R, V35T, E36A, T39D, S48T, K173A, Q174K,
D177E, I178V, V179I, T200A, Q207E, R211K
09 03/08/2006 23 F 51100 278 heterosexual M36I, I93L I13V, I15V, L19I, N37K,
R41N, H69K, T74S, L89M
None K103R,
V179D
E28K, K32E, V35T, E36A, T39D, S48T, V60I,
S68G, V90I, K122E, D123N, I135T, K173A,
D177E, T200A, E203D, Q207A, R211K
10 09/04/2007 25 M 67430 388 homosexual None M36T, N37K, R41N,
L63P, H69K, L89M, I93L
None None V10X, V35T, E36A, T39D, K43R, D121H, K122E,
D123S, K173A, D177E, Q197K, Q207K, R211K
11 4/5/2009 30 F 116623 881 heterossexual L10I E35D, M36I, N37K, R41N,
K45R, D60E, L63Q,
H69K, L89M, I93L
None None K11R, V35T, E36A, T39D, S48T, K122E, D123N,
I135T, K173A, D177E, T200A, E204K, Q207E
12 4/5/2009 29 M 63980 71 heterossexual None T12P, I15V, E35D, M36I,
N37K, R41N, K45R, D60E,
L63Q, H69K, L89M, I93L
None None V35T, E36A, T39D, K43KR, S48T, K122E,
D123N, I135T, K173A, D177E, T200A,
E204K, Q207E, V245Q
13 8/4/2010 31 M 40.557 583 heterossexual None I15V, M36I, N37K, R41N,
Q61N, L63T, H69K,
L89M, I93L
None K103N V35T, T39EK, K173A, Q174R, T200A,
Q207E, R211K
14 19/4/2010 42 M 59.024 176 heterossexual T74S I15V, M36T, N37K, R41N,
K45R, L63T, H69K, I72IV,
L89IM, I93L
None None V35T, E36A, T39E, A158S, K173A, T200A,
Q207E, V245Q
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Table 1 Epidemiological, virological, immunological characteristics and resistance associated mutations of PR/RT region from patients classified as HIV-1
(Continued)
15 5/5/2010 47 M 147.776 486 heterossexual None T12S, I15IV, L19I, T26AT,
M36I, R41K, L63V, H69K
None None V35T, E36A, T39E, E40D, K122E, D123S,
I135T, S162C, K173A, D177E, T200A,
Q207E, R211K, V245Q, E248N
16 6/5/2010 26 F 3.024 289 heterossexual None T12S, I15V, L19I, E35D,
M36L, N37K, R41N, L63P,
H69K, V82I, L89M, I93L
V118I None V35T, E36A, T39E, D121H, K122E, D123S,
I135T, T165IT, K173T, D177E, I178V,
T200A, Q207E, R211K, F214L
B- subtype BC
17 08/03/2005 43 M 5880 353 heterosexual L63P I13V, K14R, E35D,
I62V, I72V
G333A None V35T, E36A, T39D, S48ST, V60IV, K122E,
D123S, R211K, V245Q, A272P, I293V,
T296S, K311R
18 29/09/2005 40 M 14400 407 heterosexual L63P I13V, E35D, I64L, I72V None V179D K22R, V35T, E36A, T39D, S48T, D121H,
K122E, D123S, S162C, R211K, V245Q
19 09/01/2006 27 F 96300 345 heterosexual L63P I13V, E35D, I64L, I72V None V179D K22R, V35T, E36A, T39D, S48T, D121H,
K122E, D123S, R211K, V245Q
20 24/05/2007 42 M 111001 N/C heterosexual None L5F, I13V, L19V, E35D,
L63P, I72V, V77I
None M230W V35T, E36A, T39D, S48T, K122E, D123S,
T165I, R211K, Y232F
21 26/06/2008 44 F 65477 N/C Others None M36I, N37K, R41N, D60E,
I62V, L63P, H69K, I93L
M41L,
M184V,
T215F
K103S,
G190A
E28K, K32E, V35T, T39N, V60I, K101Q,
K122E, D123N, T200A, V245Q
22 26/4/2010 56 M 38550 250 heterosexual None I13V, E35D, L63P, I72V None None V35T, E36A, T39D, S48T, V60I, K122E,
D123S, R211K, V245Q
Notes: M: Male; F: Female; VL: RNA HIV viral load; CD4: CD4 T cell count; N/C: data not collected; None: no mutation was found.
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For each data set, two runs of 4 chains each (one cold
and three heated, temp = 0.20) were run for 4x107 gen-
erations, with a burn-in of 4x106 generations. Conver-
gence of parameters was assessed by calculating the
effective sample size (ESS) using TRACER v1.4 (http://
beast.bio.ed.ac.uk/Tracer./) excluding an initial 10% for
each run. All parameter estimates for each run showed
an ESS values >100. A final Bayesian majority-rule con-
sensus tree was obtained for the data set. The SplitsTree
program version 4 [42] was used to confirm the phylo-
genetic relationship of the recombinant samples using
the NeighborNet, based on the pairwise distance esti-
mated by the F84 parameter model, as GTR + I + G
model was not available in this program. Recombination
analysis was performed by bootscan analysis as imple-
mented in the Simplot version 3.5.1, [44] using group M
reference sequences representative of the HIV-1 sub-
types. Bootstrap values (>70) supporting branching with
reference sequences were determined in NJ trees con-
structed using the K2-parameter model, [45] based on
100 resamplings, with a 200 nt sliding window moving
in steps of 20 bases. In order to confirm the genetic
structure of putative recombinant viruses, NJ phylogen-
etic analyses were conducted using the fragments of
sequences assigned to specific HIV-1 subtypes according
to the proposed breakpoint position by the bootscanning
analysis.
HIV-1 subtype C and BC env sequences
The envelope gene was also sequenced when subtype C
and BC PR/RT sequences were identified. A fragment of
0.6 kb of the envelope region of the HIV-1 was amplified
by nested-PCR primers LB1 (TAGAATGTACACATGG
AATT)/, LB2 (GCCCATAGTGCTTCCTGCTGCT) as
outer primers and LB3 (GCAGTCTAGCAGAAGAAGA)/,
LB4 (CTTCTCCAATTGTCCCTCATA) as inner primers.
The sequence analysis of the env region was performed as
previously described for the PR/RT region (data not
shown).
Sequence data
All the sequences generated were submitted to the Gen-
Bank database and the assigned accession numbers were:
pol region: GU288708-GU288746, GU288748-GU288754,
GU288756-GU288776, GU288778-GU288786, GU288788-
GU288792, GU288794-GU288807, GU288809-GU288813,
JN195817-JN196018 and env region: JN196019-JN196040.
Results
Demographic and clinical data
A total of 302 HIV-1-infected patients were analyzed, of
these, 225 (75%) were men and 77 (25%) were women,
with a mean age of 36 years-old. The distribution by the
exposure categories were as follows: 61% heterosexual,
23% men who have sex with men, 9% bisexual and 7%
other. According to the clinical status, 153 patients
(72.5%) were asymptomatic, 55 (26.1%) were symptom-
atic and for 3 (1.4%), no information was obtained. The
mean RNA plasma viral load was 5.28 log10/mL and
the CD4+T cell count was 350 cells/mm3 for naïve
patients. For treated patients, 38 (46.3%) were asymp-
tomatic, 27 (33%) were symptomatic and for 17
(20.7%), no information was obtained. The mean RNA
plasma viral load was 5.0 log10/mL and the CD4
+T cell
count was 246 cells/mm3.
HIV-1 PR/RT subtype classification
According to the phylogenetic and bootscan analyses,
239 patients (79.1%) were assigned to subtype B (167
naïve, 66 treated and 6 with no information concerning
treatment-ND), 23 (7.6%) were assigned to subtype F1
(13 naïve, 8 treated and 2 ND), 16 (5.3%) were subtype
C (12 naïve, 3 treated and 1 ND), and 24 (8%) were re-
combinant forms (19 naïve and 5 treated). Among the
recombinant forms, 14 were BF recombinants
(11URF_BF1 and 3 CRF28/29), 1 BU, 1 FD, 2 FU and 6
BC recombinants (5 BC with the same PR/RT recombin-
ant patterns, in which only two of them were related
and 1 CRF31/D). The Bayesian tree of the non-subtype
B sequences is depicted in Figure 1. Interestingly, a
group of four BC sequences presenting a well supported
clustering and presenting the same recombinant pattern
was detected; further full genomic sequencing is
required in order to describe a new CRF_BC.
Primary and secondary resistance
HIV-1 primary resistance mutations were detected in 42
(20%) out of 211 naive individuals, among these, 8
(3.8%) presented major PI resistance mutations, 29
(13.7%) presented NRTI resistance mutations and 27
(12.8%) presented NNRTI resistance mutations. Overall,
20% of individuals presented resistance to one antiretro-
viral class, 7.6% presented resistance to two classes, and
2.8% presented resistance to all three classes. HIV-1 sec-
ondary resistance mutations were investigated in 82
patients receiving HAART regimen, among these, 30
(36.6%) presented major PI resistance mutations, 51
(62.2%) NRTI resistance mutations and 42 (51.2%)
NNRTI resistance mutations. Overall, 17.1% of indivi-
duals presented resistance to one antiretroviral class,
56.1% presented resistance to two classes, and 76.8%
presented resistance to all three classes.
Comparing the resistance levels in two distinct periods
of the study, 2002–2006 and 2007–2010, the following
were verified: PI resistance mutations (5.3% vs 2.6%;
p = 0.5), NRTI (12% vs 18%, p = 0.3), NNRTI (10.5% vs
18%; p = 0.18), showing an increasing trend of resistance
levels, except for PI resistance mutations. Among the 82
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treated patients, the following were verified: PI resist-
ance mutations (46.2% vs 20%; p = 0.03), NRTI (42.3% vs
56.7%; p = 0.3), NNRTI (28.8% vs 46.7%; p = 0.17), similar
results to naïve patients were observed (data not shown).
The major resistance mutations detected in PR and RT
regions in drug naïve or HAART individuals, independ-
ent of HIV-1 subtype, were: I93L, L10I/F/V, L63P, M36I/
L/V, V118I, V179D/I, as presented in Figure 2.
Secondary resistance mutations in the PR region were
detected in individuals infected with subtypes B and F1
(G73S, I50L/V, I54L, I84V, L33F, L89V, V11I, V32I), and
in the RT region (K101E, L100I, P225H, V108I, Y181C,
Y188L). The mutations K65R, Q151M, Y115F were iden-
tified only in subtype B samples.
Demographical and clinical data from individuals
classified as subtype C and BC recombinants
Since very little data is available concerning subtype C
individuals outside the southern region of Brazil, in the
present work, this group was the focus of more specific
analysis. Thus, comparisons between the 22 HIV-1 indi-
viduals classified as subtype C and BC recombinants and
subtype B individuals verified that the most common
transmission mode was sexual and mean age in both
groups was approximately 36 years-old. Interestingly, in
the subtype C and BC recombinants group, 7 (31.8%)
were women and 16 (72.7%) were asymptomatic. The
mean viral load and CD4+ T cells counts were 4.64
log10/mL and 281 cells/mm
3, respectively, in naive
patients, while for patients receiving HAART treatment,
the means were 4.23 log10/mL and 34 cells/mm
3, re-
spectively. Among HIV-1-infected individuals in the sub-
type B group, 47 (19.7%) were women and 155 (64.9%)
were asymptomatic (p = 0.97 and p = 0.76; respectively).
The means for viral load and CD4+ T-cells counts were
5.33 log10/mL and 349 cells/mm
3, respectively, for naive
patients, while for patients receiving HAART, the means
were 5.02 log10/mL and 249 cells/mm
3, respectively.
An increasing trend of subtype C and BC was
observed, increasing from two cases from 2003 to 2006,
to 20 cases from 2007 and 2010 (p < 0.05).
Sixteen out of 22 (72.7%) subtype C or BC recombinant
individuals were naïve and the main mutations identified in
the PR/RT region were G333A, I93L, L63P, M36I/T, V118I.
Five (22.7%) were receiving treatment and the main muta-
tions identified were I93L, L63P, M36I/T, M41L, M184V,
T215F (to a lesser extent) and for 1 (4.6%) subtype C and
BC individual, no information concerning treatment was
Figure 1 Majority-rule Bayesian consensus tree of the pr/rt region (860nt) from non subtype B samples collected in Sao Paulo city
from 2002 to 2010. Posterior probability values superior to 0.80 are indicated. The sequences described in the present study were star marked.
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available. For subtype B individuals, 167 (69.9%) were naïve
patients and the main mutations identified were: D67N,
K70R, G190A/S, L90M, T69A/D/N/S. Sixty six (27.6%)
were receiving treatment and the main mutations identified
were A98G, D30N, L74I/V, L210I/M/W, N88D, T69A/D/
N/S, V90I, V106I/M, and for 6 (2.5%) individuals, no infor-
mation concerning treatment was available. These muta-
tions were verified only in the subtype B group.
Only two cases (2/16) showed non-analogue nucleo-
tide drug resistance mutation for subtype C, while four
cases (4/6) showed non-analogue nucleotide drugs re-
sistance mutation for subtype BC in naïve patients.
The demographical and clinical data for subtype C and
BC recombinant patients with the mutations identified
in this cohort are listed in Table 1A and B.
Discussion
As expect, the HIV-1 B was the most common subtype
in the cohort (79.1%) followed by subtype F1 (7.6%). A
relevant presence of subtype C (5.3%) was observed and
an increase in the number of mosaics (8%), of which 2%
were BC recombinants. The first identified case of HIV-
1 subtype C in this cohort from the city of São Paulo
was from 2003, even though this cohort has been
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Figure 2 Frequency of the main associated resistance mutations in naïve and HAART patients according to the viral subtype.
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ollowed since 1989. In fact, this subtype predominates in
South, where the majority of counties present the high-
est rates of HIV-1 infection in Brazil, [46] in contrast
with Southeastern, where a small incidence of around
3% of subtype C is observed [16,27]. However, the
present study and other more recent studies have docu-
mented an increased prevalence of this subtype outside
of the Southern region [30,47].
The present cohort was predominantly naive hetero-
sexual patients for all HIV-1 subtypes. The mode of
transmission for HIV-1 C was clearly associated with
heterosexual contact, similar to the major source for this
subtype in Africa and Asia [27]. Thus, its presence in
the city of São Paulo and the increasing number of cases
seem to indicate that subtype C has increased transmis-
sion capacity, as occurred in Asia and Africa, the epicen-
ter of the pandemic [30]. It is too early to determine
whether the presence of viruses with molecular charac-
teristics of other subtypes has clinical or epidemiological
importance, but it certainly indicates the dynamics of
the epidemic, with the number of new infections and
high prevalence of various subtypes circulating in the
Brazilian population.
Recombinations between subtypes B and C have been
identified among the HIV-1 samples obtained in South-
ern Brazil, [22] and now in this cohort. Although sub-
type C is responsible for more than 56% of HIV-1
infections worldwide, up to now, only four out of the 49
known CRFs involving recombinations with subtype C
have been described worldwide: CRF07_BC, CRF08_BC,
CRF10_CD and CRF41_CD (CRF41_CD, has not yet
been published) [14,15,17]. So far, only one of these is
present in Brazil, [18] CRF31_BC [16]. The five BC
recombinants identified in this work could represent a
new CRF_BC, but full genomic analysis is required to
elucidate this possibility.
As previously described, the prevalence of resistance
associated mutations appear to differ between subtype
B and others (non-B), selected mutations in codons
41, 210 and 215 are more frequent in the former,
whereas mutations at codon 67, 70 and 219 are more
common in subtype C [31]. The L210W mutation
appeared in subtypes B and F, while the mutation
L210I/M appeared only in subtype BU. The common
resistance associated mutations for all HIV-1 subtypes
are 118, 184 and 215. Mutations M36I, L63P, L89M,
and I93L are related to antiretroviral resistance in sub-
type B and have also been identified in subtype C as
polymorphisms, [48] these mutations were also verified
in patients from the present cohort. In the samples
obtained here, the most common resistance associated
mutations detected in all HIV-1 subtypes were: PI
codons 10, 36, 63 and 93 and NNRTI codons 179 and
190. The K103N mutation was not observed in the
mosaics samples and the V90I mutation was not veri-
fied in subtype F.
The mutation V106M was previously described as oc-
curring rapidly in subtype C virus, leading to high level
of resistance, [47] even though it was not verified in the
samples obtained here. This mutation may be a signa-
ture in subtype C patients treated with efavirenz and
may have the potential to confer high-level multi-
NNRTI resistance [19,48]. Differential drug resistance
acquisition was verified among subtypes B and C, in
which subtype C viruses apparently acquired a lower
number of mutations than subtype B for PI and NRTI,
but not for NNRTI [7]. As previously described, our
group also observed that the proportion of subtype C or
BC mosaics among naive cases is significantly higher
than among treated individuals, corroborating the hy-
pothesis of more recent introduction of this subtype and
recombinants in the Southeastern region [30].
In conclusion, the percentage of subtype C, BC and
CRFs could be increasing in the city of São Paulo in re-
cent years. Molecular epidemiological information con-
cerning HIV-1 strains is proving to be important in
elucidating the dynamics of HIV spread and the formula-
tion of future vaccine strategies.
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